mTOR-Driven IL-6 Triggers Lung Cell Senescence and Blocks Repair in Rare Disease

LAM is a rare, progressive, and predominantly female lung disease in which TSC2-deficient 'LAM cells' with constitutively active mTOR signaling accumulate in the lung, forming destructive nodules that cause cyst formation and respiratory failure. Despite treatment with mTOR inhibitors like rapamycin, the disease is not cured and lung function continues to decline, implying additional pathological mechanisms are at play. This study investigates whether mTOR dysregulation triggers cellular senescence in lung epithelial cells, thereby impairing the tissue repair processes needed to counteract ongoing damage.

Using single-cell RNA sequencing data from the LAM cell atlas (13 lung transplant donors), immunohistochemistry of 21 LAM lung and 3 control samples, laser-capture microdissection RNA sequencing of LAM nodules from 19 patients, and a murine homograft model (TSC2-null cell injection into immunocompetent C57BL/6 mice), the researchers comprehensively characterized the senescence landscape in LAM. They found that the canonical CDK inhibitors p21 (CDKN1A) and p16 (CDKN2A) were broadly elevated in LAM lung cells, with p21 particularly enriched in pre-alveolar type-1 transitional cells (PATS)—intermediate cells that fail to fully differentiate and may reflect impaired repair. Senescence-associated beta-galactosidase activity was also over two-fold higher in murine LAM models compared to controls.

A key mechanistic finding is that LAM cells produce IL-6 in a manner dependent on mTOR activity, and this secreted IL-6 acts in a paracrine fashion to induce p16 and p21 expression in AT2 cells—the alveolar stem cell population essential for regenerating damaged lung epithelium. In vitro AT2 organoid models and co-culture experiments demonstrated that conditioned media from LAM cells, or exogenous IL-6 alone, was sufficient to trigger AT2 senescence. Furthermore, IL-6 levels correlated inversely with lung function (FEV1 % predicted) in LAM patients, linking this cytokine to clinical disease severity. Importantly, the senescence-associated secretory phenotype (SASP) produced by senescent cells can propagate senescence to neighboring cells, creating a self-amplifying cycle of damage.

Targeting this pathway therapeutically proved effective in laboratory models. Rapamycin reduced IL-6 secretion by LAM cells and attenuated AT2 organoid p21 accumulation. The IL-6 receptor antagonist Tocilizumab—already approved for rheumatoid arthritis and cytokine storm syndromes—further reduced AT2 senescence and, crucially, enhanced epithelial wound repair in scratch-assay models where IL-6 had impaired healing. These findings suggest that combining mTOR inhibition (to suppress IL-6 production) with IL-6 receptor blockade (to interrupt paracrine senescence signaling) could offer a more complete therapeutic strategy than mTOR inhibition alone.

The study provides a compelling mechanistic framework linking mTOR hyperactivation → IL-6 secretion → paracrine AT2 senescence → impaired lung regeneration in LAM. While work was primarily conducted in cell and animal models with some human tissue validation, the findings open a credible therapeutic avenue. The presence of PATS cells—previously identified in other lung injury contexts and now in LAM—further supports the concept of a shared final pathway of impaired epithelial repair across lung diseases involving cellular senescence.